Analysts expect Pfizer Inc. (NYSE: PFE) to report earnings of $ 1.12 per share for the current fiscal quarter, according to Zacks. Three analysts made estimates for Pfizer’s earnings, with the lowest EPS estimate at $ 0.96 and the highest estimate at $ 1.24. Pfizer posted earnings per share of $ 0.72 in the same quarter last year, suggesting a positive year-over-year growth rate of 55.6%. The company is expected to release its next results on Tuesday, October 26.

On average, analysts predict that Pfizer will report annual earnings of $ 4.09 per share for the current year, with EPS estimates ranging from $ 3.64 to $ 4.40. For the next fiscal year, analysts expect the company to post earnings of $ 3.52 per share, with EPS estimates ranging from $ 2.87 to $ 4.24. Zacks Investment Research EPS averages are an average based on a survey of sell-side research analysts who cover Pfizer.

Pfizer (NYSE: PFE) last released its results on Wednesday, July 28. The biopharmaceutical company reported earnings per share of $ 1.07 for the quarter, beating consensus analysts’ estimates of $ 0.97 per $ 0.10. The company posted revenue of $ 18.98 billion for the quarter, compared to $ 17.54 billion expected by analysts. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. In the same quarter of the previous year, the company achieved EPS of $ 0.78.

Several brokerages recently commented on PFE. Truist began covering Pfizer shares in a report on Tuesday, July 27. They set a “buy” rating and a price target of $ 43.00 for the stock. Morgan Stanley raised its price target for Pfizer shares from $ 42.00 to $ 45.00 and gave the company an “equal weight” rating in a report released Thursday, July 29. Mizuho reiterated a “hold” note and set a price target of $ 43.00 on Pfizer shares in a report released on Sunday. JPMorgan Chase & Co. raised its price target for Pfizer shares from $ 40.00 to $ 42.00 and gave the company a “neutral” rating in a report released on Monday, September 13. Finally, the Goldman Sachs group set a price target of $ 48.00 on Pfizer shares in a report released on Thursday, July 29. Eleven equity research analysts rated the stock with a conservation rating and two gave the company’s stock a buy rating. According to MarketBeat.com, Pfizer has an average “Hold” rating and a consensus price target of $ 42.85.

Pfizer shares traded up $ 0.06 during trading hours on Tuesday, reaching $ 42.48. The company’s shares had a trading volume of 681,598 shares, compared to its average volume of 30,598,568. The company has a 50-day moving average price of $ 45.67 and a 200-day moving average price. of $ 41.24. Pfizer has a one-year minimum of $ 33.36 and a one-year maximum of $ 51.86. The company has a debt ratio of 0.50, a current ratio of 1.37, and a quick ratio of 1.12. The stock has a market cap of $ 238.17 billion, a P / E ratio of 18.23, a P / E / G ratio of 1.58 and a beta of 0.74.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 6. Shareholders of record on Friday, November 5 will receive a dividend of $ 0.39 per share. This represents a dividend of $ 1.56 on an annualized basis and a return of 3.67%. The ex-dividend date is Thursday, November 4. Pfizer’s dividend payout ratio (DPR) is currently 70.27%.

In other Pfizer news, SVP Jennifer B. Damico sold 1,661 Pfizer shares in a trade dated Friday, August 13. The shares were sold at an average price of $ 48.30, for a total trade of $ 80,226.30. The sale was disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. In addition, SVP Jennifer B. Damico sold 2,500 Pfizer shares in a transaction that took place on Friday, July 30. The shares were sold at an average price of $ 42.86, for a total trade of $ 107,150.00. Following the closing of the transaction, the Senior Vice President now owns 11,430 shares of the company, valued at approximately $ 489,889.80. Disclosure of this sale can be found here. 0.05% of the shares are held by insiders of the company.

Major investors have recently bought and sold shares in the company. GoalVest Advisory LLC acquired a new stake in Pfizer in the second quarter for a value of approximately $ 39,000. Benjamin Edwards Inc. increased its stake in Pfizer by 36.5% in the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company valued at $ 36,000 after acquiring 267 additional shares during the last quarter. Alpha DNA Investment Management LLC increased its stake in Pfizer by 52.2% in the 1st quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company valued at $ 39,000 after purchasing 374 additional shares in the last quarter. Lake Point Wealth Management purchased a new position in Pfizer in the second quarter valued at approximately $ 49,000. Finally, Harvest Fund Management Co. Ltd increased its stake in Pfizer by 25,460.0% in the 2nd quarter. Harvest Fund Management Co. Ltd. now owns 1,278 shares of the biopharmaceutical company valued at $ 50,000 after purchasing an additional 1,273 shares in the last quarter. 64.93% of the shares are currently held by institutional investors and hedge funds.

About Pfizer

Pfizer Inc is a global research-driven biopharmaceutical company. It is dedicated to the discovery, development, manufacture, marketing, sale and distribution of biopharmaceuticals worldwide. The firm works in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read more: What is the meaning of the cross of death?

Get a Free Copy of Zacks’ Pfizer Research Report (PFE)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Pfizer now?

Before you consider Pfizer, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Pfizer was not on the list.

While Pfizer currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here